SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is at the center of investor focus as its Worldwide Developers Conference triggers aggressive volatility and a classic 'sell the news' reaction, with the community intensely debating the impact of its new AI strategy and reliance on Google Cloud infrastructure. Traders are closely monitoring key support levels near $300 and discussing whether the stock's high valuation is justified following the mixed reception of its latest AI features.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending following reports of a major AI chip deal with ByteDance and an upbeat outlook on its data center and automotive segments, fueling investor excitement about the company's pivot beyond mobile handsets. Community members are actively debating the stock's valuation as it tests all-time highs, with many traders analyzing whether the company can successfully capture a larger share of the AI infrastructure market against competitors.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing intense downward pressure as investors rotate out of software and mega-cap tech amid concerns over heavy AI-related capital expenditures and broader market volatility. The community remains deeply divided, with bears pointing to the stocks recent decline as evidence of an overvaluation and a lost AI race, while bulls view the pullback as a long-term entry opportunity into a fundamentally strong, free-cash-flow-positive giant.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending after securing a major 15-year lease for its fifth AI campus, driving a massive increase in total contracted revenue and fueling community excitement over the company's rapid expansion. Investors are actively discussing the firm's robust backlog, the role of investment-grade hyperscalers, and expectations for a significant stock re-rating as these projects shift from development to operational cash flow.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is seeing intense community scrutiny as investors express deep frustration over the company's communication, leadership, and management's requests for additional equity compensation despite a stagnant share price. Meanwhile, discussions have shifted toward Novavax's proprietary combination vaccine assets and potential involvement in emerging Ebola outbreak responses as critical catalysts that the community believes management must capitalize on to drive value.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve Cannabis is trending as investors rally ahead of the company's highly anticipated NYSE uplisting scheduled for June 10th. The community is focused on the potential for increased institutional inflows, while debates persist over market volatility, regulatory risks, and the company's strategic position as a leader in the U.S. medical cannabis market.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant investor attention as the community anticipates imminent 52-week clinical data, which is widely viewed as a pivotal catalyst for a potential M&A event. Traders are actively discussing the stock's positioning ahead of major industry conferences, with many speculating that strong data could trigger a bidding war among major pharmaceutical suitors.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as investors monitor reports that U.S. antitrust regulators appear increasingly willing to approve the Warner Bros. Discovery acquisition following constructive meetings regarding theatrical release commitments. The community remains deeply divided, with some shareholders expressing frustration over prolonged price suppression and ongoing litigation hurdles while others maintain confidence that the strategic merger will ultimately unlock long-term value.

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.

Nurix Therapeutics Inc

Nurix Therapeutics is currently in the spotlight following the announcement of a multibillion-dollar collaboration with Roche to develop a blood cancer drug, a move seen by the community as major validation for their targeted protein degradation platform. While some analysts have adjusted their price targets, investors are actively debating the long-term potential of this deal, with many focusing on the bolstered cash position and the reduction of future development risk.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is facing extreme downward pressure, hitting multi-year lows that have fueled intense community debate over whether the stock is an overlooked value play or a long-term trap. Investors are actively discussing the potential for a rebound driven by institutional accumulation, AI integration, and core business restructuring, while detractors point to poor revenue growth and persistent underperformance compared to the broader fintech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials

Equity

Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in three late-stage trials.


Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials PR Newswire INDIANAPOLIS, June 8, 2026...

Jim Cramer says he can't sell Eli Lilly despite its massive run up. Here's why

"I think the majority view is that Lilly is pulling away, kind of Secretariat-like," Jim Cramer said Monday...

A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.

Key PointsZealand Pharma reported a high drop-out rate in a phase III trial of Survodutide, due to undesirable side effects experienced by patients...

Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?

ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.

ALT and the Rise of Dual Agonists Targeting Liver Disease

Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.

ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup

Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.

Is Altimmune Worth Buying Ahead of 2026 Catalysts?

ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.

Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg

Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.

Zacks Investment Ideas feature highlights: Eli Lilly and Merck

Health care's seasonal strength and defensive appeal are in focus, with Eli Lilly's growth and Merck's pipeline progress highlighted as key drivers.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$8.81	--	--	N/A
Q1 '26	$6.97	$8.55	22.71%	BEAT
Q4 '25	$6.91	$7.54	9.10%	BEAT
Q3 '25	$5.69	$7.02	23.33%	BEAT
Q2 '25	$5.60	$6.31	12.70%	BEAT

LLYLilly(Eli) & Co

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest LLY News